India’s Pharmaceutical Production Linked Incentive (PLI) scheme was designed to strengthen domestic manufacturing, attract investment and encourage companies to move towards higher-value pharmaceutical products. With a financial outlay of ₹15,000 crore, the scheme has supported manufacturing expansion across the pharmaceutical sector. But for India’s micro, small and medium enterprises (MSMEs), the bigger question is whether this investment is translating into stronger technological capabilities, improved quality systems and sustainable export growth.
The challenge is significant. Smaller pharma manufacturers play an important role in domestic medicine supplies, contract manufacturing, employment generation and exports. However, they often operate with tighter budgets and have less access to capital, research facilities, advanced technology and specialist regulatory expertise. This can make it difficult for them to compete with larger Indian companies and international manufacturers.
The government has recognised these differences in the design of the pharma PLI scheme. Of the 55 applicants selected, 20 are MSMEs, accommodated within Group C, which has a dedicated framework for smaller manufacturers.
However, industry representatives argue that a separate framework is only the starting point. Smaller companies need practical access to finance, technology, quality expertise and export markets if they are to turn manufacturing investment into sustainable growth.
Ajay Singh Dassundi, Secretary of the MP Small and Medium Drugs Manufacturers Association, says the scheme is a positive initiative, but its benefits have been relatively limited for MSMEs compared with companies that have the financial strength and scale to make large investments.
“The next phase must ensure that the benefits of the PLI Scheme reach not only large manufacturers but also the thousands of MSMEs that form the backbone of India’s pharmaceutical industry,” he says.
Investment, but for whom?
A government update published in January 2026, reporting progress through September 2025, said the scheme had attracted investment of ₹40,294 crore against a targeted ₹17,275 crore. Cumulative sales stood at ₹3,08,408.60 crore, including exports of ₹1,98,509.49 crore. The government also reported an employment generation of approximately 97,000 people, including contractual and apprentice workers.
For Namit Joshi, Chairman of Pharmexcil, this distinction is crucial.
“The impact of the scheme is more clearly visible in terms of manufacturing investment and capacity creation,” he says, cautioning that it would be premature to attribute a substantial expansion in international market presence specifically to PLI-supported MSMEs without more detailed data.
“Investment and production figures indicate whether manufacturing activity is expanding. They do not necessarily show whether smaller companies are adopting advanced technologies, entering new markets or developing higher-value products. The next phase should focus on helping these businesses convert manufacturing capabilities into tangible and sustained export outcomes,” Joshi adds.
“The ultimate test is whether MSMEs are becoming stronger businesses that can invest independently, create employment, develop better products, enter new markets, and sustain their growth beyond the incentive period,” he says.
Group C: A step towards a level playing field?
The creation of a dedicated MSME framework within Group C reflects the government’s recognition that smaller manufacturers cannot always meet investment requirements designed for large pharmaceutical companies.
The changes introduced to the scheme’s operational guidelines in 2024 were intended to improve access for MSMEs. However, a separate eligibility framework does not automatically eliminate the financial and administrative challenges of participating.
Suveer Shrivastava, former Chief Quality Officer and Sr VP of Regulatory Affairs, believes the changes are a positive step, but their effectiveness will depend on implementation.
“Introducing a separate framework is only the first step. Its effectiveness will depend on how well the provisions are implemented and monitored,” he says.
Shrivastava argues that eligible MSMEs need to receive the intended benefits without being disadvantaged by limited financial resources or administrative capabilities. He also recommends greater involvement of independent third-party experts and relevant State Food and Drug Administrations in monitoring implementation and assessing outcomes.
For Bhavin Mehta, Whole-Time Director of Kilitch Drugs (India) and Vice-Chairman of Pharmexcil, accessibility and predictability are equally important.
“Clear eligibility criteria, streamlined documentation, transparent evaluation processes and predictable timelines for incentive disbursement can help businesses plan investments with greater confidence,” he says.
Dassundi welcomes the separate framework but stresses that the eligibility criteria, investment thresholds, incentive structure and application procedures must be realistic for smaller manufacturers.
“For a small or medium manufacturer, even an investment of a few crores can be a significant financial commitment,” he says.
Mehta says the framework should be practical enough for eligible companies to navigate while retaining performance requirements to ensure that public incentives support genuine manufacturing activity. He recommends clear guidance, efficient administration and regular assessment of the capabilities being developed.
As Dassundi puts it, “MSMEs do not necessarily need protection from competition; they need the financial and technological capabilities to compete.”
One of the biggest challenges facing pharma MSMEs is the cost of upgrading existing manufacturing facilities.
Pharma production requires qualified equipment, validated processes, reliable documentation and effective quality management systems. Companies seeking to supply regulated international markets must also meet the requirements of their target markets, which can require substantial investment in infrastructure, technology and personnel.
For a smaller manufacturer, such investment can be difficult to finance alongside day-to-day operations.
Narotam Juneja, Technical Advisor at Uniserum Lifesciences, identifies infrastructure modernisation as a major concern, particularly for businesses operating older facilities. Upgrading these plants to meet current good manufacturing practice (GMP) requirements and international regulatory standards requires substantial capital expenditure.
Companies unable to make the necessary changes may face regulatory action, including suspension of operations or cancellation of manufacturing licences. The result is a difficult investment choice: a company may need to spend heavily simply to maintain its existing manufacturing capabilities, leaving fewer resources for new products, automation or export expansion.
Dassundi identifies high investment requirements as one of the principal barriers to MSME participation. Modern pharmaceutical manufacturing requires spending on plant and machinery, laboratory facilities, automation, validation and regulatory compliance. At the same time, high borrowing costs, collateral requirements, working-capital constraints and long payment cycles can prevent smaller companies from financing expansion.
The challenges extend beyond capital expenditure. Smaller businesses may not have dedicated teams to manage incentive applications, compliance requirements and the documentation needed for international markets. Many also lack the resources to establish sophisticated research facilities or maintain specialised research and development teams.
Juneja also points to the challenges MSMEs face when attempting to enter higher-value product categories.
Developing complex generics and other advanced pharmaceutical products can require significant expenditure on research and development, specialised equipment, regulatory documentation and compliance. For a smaller company, the financial risk can be considerably higher than for a large manufacturer with a broader portfolio and greater access to capital.
Research-driven MSMEs may also face a first-mover disadvantage when they have to finance trials and generate regulatory data before commercial returns become visible. These challenges suggest that the next phase of PLI should pay closer attention to the quality and purpose of investment, rather than focusing primarily on the amount committed.
Shrivastava argues that MSMEs need to move beyond a narrow focus on production volumes and short-term financial performance.
“Investments in quality, innovation, and digitalisation are not merely compliance expenses; they are essential to sustainable growth and access to higher-value markets,” he says.
He identifies automation, data integrity, robust quality management and workforce development as important areas for improvement. For smaller manufacturers, however, adopting these capabilities may require technical expertise that is difficult to recruit or retain in-house.
Shrivastava therefore proposes a structured technical guidance and mentoring programme involving experienced pharmaceutical professionals. Such a programme could help companies identify compliance gaps, develop improvement plans and implement stronger manufacturing and quality systems. Shared technical infrastructure, specialised training and independent assessments could also help smaller businesses address capability gaps without bearing the full cost of developing every resource independently.
Dassundi recommends a more integrated support system. Alongside incentives, he wants government-backed credit guarantees, interest subvention and concessional financing to help MSMEs fund technology upgrades and capacity expansion.
He also proposes affordable research and development facilities, common testing laboratories, pilot-scale manufacturing facilities and technology-transfer programmes developed in collaboration with government-supported research institutions.
Opportunity comes with risk
Moving towards higher-value pharma products is a key ambition of the PLI scheme. It offers Indian manufacturers an opportunity to develop specialised capabilities and compete in segments where technology, quality and regulatory expertise are critical.
For MSMEs, however, entering these categories is not simply a matter of installing new equipment.
Depending on the product, companies may need to invest in research, process development, specialised analytical capabilities, validation, regulatory submissions and skilled personnel. These investments can take time to generate revenue and may not always lead to commercial success.
Juneja argues that smaller manufacturers can be structurally disadvantaged because of the higher capital and compliance costs associated with developing complex products. He also highlights the difficulty of funding innovation when the first applicant bears substantial costs for trials and regulatory data, while subsequent entrants may have access to less expensive regulatory pathways.
The next phase of PLI could address this challenge by encouraging product diversification alongside targeted technical and regulatory support.
Mehta believes the long-term impact of PLI will depend on whether manufacturing investment translates into sustainable business growth.
“In segments such as sterile injectables, this requires more than production capacity alone,” he says. “Companies must build strong process validation systems, maintain consistent product quality, secure regulatory approvals and establish dependable supply relationships with customers across markets.”
Dassundi also believes that the next phase should support MSMEs in moving up the value chain, developing differentiated products and building sustainable export businesses rather than simply increasing the volume of conventional products.
Can MSMEs crack exports?
India’s pharma industry has an established presence in international markets. According to the Ministry of Commerce and Industry, pharmaceutical exports reached approximately $30.47 billion in FY2024-25, registering growth of 9.4 per cent over the previous financial year.
For smaller manufacturers, moving from domestic production to international sales requires capabilities that extend beyond manufacturing.
Companies must secure the necessary product registrations, meet the regulatory requirements of their target markets, maintain consistent quality and supply, and develop distribution or customer relationships overseas. These activities require time, money and specialised knowledge. Smaller exporters may struggle to absorb the costs, particularly when they have a limited product portfolio.
Joshi says Indian MSMEs must compete on cost, quality, consistency of supply and compliance with international regulatory standards.
“Manufacturing competitiveness and export competitiveness are not the same,” he emphasises.
He points to the advantages enjoyed by countries such as China in manufacturing scale, supply-chain integration and access to raw materials. For smaller Indian companies, technology upgrades, regulatory approvals, product development and market entry can create substantial additional costs.
“Tariff and non-tariff barriers add to the challenge. Changes in regulatory requirements, product-registration procedures and market-access conditions can make exporting more expensive and time-consuming for businesses with limited resources. Larger exporters are generally better placed to spread these costs across multiple products and markets. MSMEs often have less flexibility,” Joshi says.
“Manufacturing investment and production remain important, but they should be viewed as intermediate outcomes rather than the ultimate measure of success,” he says.
Joshi recommends greater emphasis on incremental exports, international product registrations, technology adoption, productivity improvements and the development of higher-value products. These measures, he argues, would help determine whether PLI-supported businesses are developing the capabilities required to compete internationally, rather than simply expanding domestic capacity.
Dassundi agrees that MSMEs can play a larger role in pharmaceutical exports, but says growth requires regulatory preparedness, consistent quality, product development, international marketing and reliable working capital.
“The next phase should help MSMEs move up the value chain, develop differentiated products, and build sustainable export businesses rather than simply increase the volume of conventional products,” he says.
Mehta also stresses the need to align manufacturing investments with international demand. Companies must understand the requirements of their intended markets and ensure that their products, facilities and supply systems can meet them.
Quality is non-negotiable
For pharma companies, quality is central to market access and commercial credibility.
Manufacturers must maintain effective quality management systems, validate processes, qualify equipment, preserve reliable records and ensure that employees are trained to perform their responsibilities. For MSMEs seeking to enter highly regulated markets, gaps in documentation, data integrity or process control can become significant obstacles.
Shrivastava believes one of the biggest challenges is translating regulatory requirements into consistent practice on the manufacturing floor. He identifies quality management, documentation, data integrity, process validation, equipment qualification, automation and workforce competence as areas requiring attention.
Dassundi proposes common skill-development centres that provide practical training in advanced manufacturing, automation, quality assurance, regulatory compliance and modern pharmaceutical technologies. Such shared facilities could give smaller businesses access to training and expertise that may be difficult to fund independently.
Mehta similarly argues that modern infrastructure, automation and robust quality systems are essential if Indian manufacturers are to remain competitive. For MSMEs, quality improvements should not be treated as a one-time exercise. They must become part of everyday manufacturing practice.
Is the framework tilted towards larger companies?
A central concern among industry representatives is whether companies with greater financial strength are better positioned to benefit from incentive-linked manufacturing schemes.
Large pharma companies generally have more resources to fund capital expenditure, recruit specialist teams and manage complex documentation and reporting requirements. Smaller businesses may struggle to make substantial upfront investments while continuing to finance routine operations.
Juneja argues that qualifying thresholds and investment commitments need to reflect the practical realities of smaller manufacturers. MSMEs may find it difficult to fund eligible greenfield projects or major expansions and wait through prolonged gestation periods before the investment begins generating returns.
His recommendation is for a more MSME-focused assessment of eligibility thresholds, qualifying investments and performance measures. The objective should be to help smaller companies upgrade existing facilities, meet higher regulatory standards, invest in product development and progressively increase the share of higher-value products in their portfolios.
Shrivastava also believes that the framework should focus more on technical capability, quality performance and the potential for sustainable growth.
“The objective should not be to give smaller companies an advantage simply because they are small, but to ensure that technically capable MSMEs are not excluded because they lack the financial and administrative resources of larger competitors,” he says.
Dassundi calls for a dedicated MSME incentive window with a defined allocation and proportionate eligibility criteria. He believes this would help ensure that eligible smaller manufacturers receive meaningful access to the scheme.
He also recommends simpler application procedures, predictable incentive payments and dedicated facilitation mechanisms. For MSMEs with limited administrative resources, a complicated application process can become an additional barrier even when a project is technically suitable.
The policy challenge is to balance accountability for public spending with a process that smaller companies can realistically navigate.
What should PLI 2.0 measure?
Joshi wants the next phase to place greater emphasis on incremental exports, international registrations, technology adoption, productivity and higher-value products.
Mehta highlights sustainable business growth, modern manufacturing infrastructure, quality systems and export readiness. Juneja stresses the need to address investment barriers, facility upgrades and the costs of developing higher-value products.
Shrivastava calls for a robust and transparent mechanism to measure the scheme’s actual benefits, including independent impact assessments comparing companies’ performance before and after receiving support.
Dassundi recommends evaluating a wider range of outcomes, including investment in infrastructure, incremental production, technology adoption, research and development, API manufacturing, exports, employment, quality and compliance, financial sustainability, MSME participation and movement towards higher-value products.
“I would particularly emphasise incremental exports, technology adoption, innovation, and sustainable financial performance,” he says.
Together, these recommendations suggest several areas for a more comprehensive assessment such as :
Investment and production: Has the scheme encouraged additional manufacturing investment and eligible sales, and how much of that activity is attributable to participating MSMEs?
Technology and productivity: Have MSMEs adopted modern equipment, automation or digital systems, and have these changes improved manufacturing performance?
Quality and compliance: Have companies strengthened quality management, data integrity, process validation and workforce competence?
Product development and exports: Have manufacturers introduced higher-value products, obtained international registrations, entered new markets or expanded repeat export business?
Financial sustainability: Can businesses maintain upgraded facilities, finance future investment and compete commercially after the incentive period ends?
MSME participation and employment: How many eligible MSMEs have received incentives and completed their projects? Have the investments generated skilled jobs and improved workforce capabilities?
Beyond incentives
India’s pharma PLI scheme has helped stimulate manufacturing investment and create opportunities for domestic producers. Its dedicated framework for MSMEs recognises that smaller companies face different financial and operational constraints from larger manufacturers.
But the industry’s challenge now is to translate participation into capability.
Dassundi’s recommendations include government-backed credit guarantees, interest subvention and concessional financing; affordable research and development facilities; common testing and skill-development centres; technology upgrades; support for API manufacturing; and stronger export facilitation. He also calls for closer collaboration between MSMEs and research institutions to make advanced technologies and product-development capabilities more accessible.
For Joshi, the priority is to link manufacturing support more closely with export readiness and measurable improvements in competitiveness. Mehta similarly sees the opportunity in helping manufacturers develop more specialised capabilities and participate more meaningfully in global value chains.
For Shrivastava, the ultimate measure is whether the scheme creates stronger, more innovative and quality-driven businesses. Juneja’s recommendations underline the need to ensure that investment requirements and eligibility criteria reflect the circumstances of smaller manufacturers.
As Dassundi concludes, the objective should not simply be to create a few large manufacturing capacities. It should be to build a broad base of technologically advanced, financially sustainable and globally competitive Indian pharma manufacturers.